HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Table 4

Univariate predictors of treatment response for HER2+ breast cancer patients receiving neoadjuvant chemotherapy.

Variable	OR (95% CL OR)	value
Age	1.01 (0.99-1.04)	0.3758
HER2 absolute copy number	1.07 (1.03-1.1)	<0.0001
HER2/CEP17 ratio	1.07 (1.02-1.14)	0.0142
IHC_STAIN_PER		<0.0001^a
3+ 100% vs. 2+	6.49 (2.60-16.25)	<0.0001
3+ <100% vs. 2+	1.88 (0.63-5.61)	0.2612
Clinical stage		0.0246^a
1 vs. 3	4.78 (1.64-15.41)	0.0067
2 vs. 3	1.58 (0.81-3.12)	0.1797
Tumor grade biopsy		0.4041^a
I vs. III	0.16 (0.0-5.44)	0.3294
II vs. III	0.73 (0.4-1.36)	0.3231
Pretreatment tumor size	0.85 (0.74-0.97)	0.0142
ER expression
Negative (<10%)	2.03 (1.08-3.90)	0.0304
Positive (10-100%)	Ref.
Hormone sensitive (ER or PgR+)
Negative (<10%)	2.44 (1.32-4.53)	0.0046
Positive (10-100%)	Ref.

Probabilities modeled are cumulated over the lower ordered RCB values. ^a value is associated with Type 3 analysis of effects.